The effects of the angiotensin converting enzyme (ACE) inhibitor captopril (SQ 14225) on intraocular pressure (IOP) were studied. Four groups were analyzed: group A, ten control subjects; group B, ten hypertensive patients with normal IOP; group C, ten normotensive patients with primary open angle glaucoma (POAG); and group D, ten hypertensive patients with POAG. Systolic and diastolic blood pressure, heart rate, pupil diameter, IOP and total outflow facility were recorded at baseline and at 1-h intervals up to 3h after an oral dose of 25 mg captopril or placebo, given in a randomized, double-blind cross-over fashion. The alternative treatment was given a week later.
Captopril significantly lowered IOP in all patients, with no effects on heart rate and pupil diameter. Blood pressure changed only in patients with hypertension (groups B and D). Total outflow facility, measured by conventional tonography, increased significantly in all groups. These findings indicate that oral captopril could represent a new antiglaucomatous compound.
TigerstedtR., BergmanP.G.Niere und Kreislauf. Skand Arch Physiol1898; 223: 310–5.
2.
GoldblattH., LynchJ., HanzalR.F., SummervilleW.W.Studies on experimental hypertension, production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med1934; 59: 347–79.
3.
CrockerD.W., NewtonR.A., MahoneyE.M., HarrisonJ.H.Hypertension due to primary renal ischemia. A correlation of juxtaglomerular cell counts with clinicopatholog-ical findings in twenty-five cases. N Engl J Med1962; 267: 794–800.
4.
DeodharS.D., HaasE., GoldblattH.Production of antire-nin to homologous renin and its effect on experimental renal hypertension. J Exp Med1964; 119: 425–32.
5.
ChristliebA.R., BiberT.U.L., HicklerR.B.Studies on the role of angiotensin in experimental renovascular hypertension: an immunologic approach. J Clin Invest1969; 48: 1506–18.
6.
BingJ., PoulsenK.Effect of anti-angiotensin II on blood pressure and sensitivity to angiotensin and renin. Acta Pathol Microbiol Scand1970; 78: 6–18.
StreetenD.H.P., AndersonG.H., FreibergJ.M., DalakosT.G.Use of angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension. N Engl J Med1975; 292: 657–62.
9.
FerreiraS.H.A bradykinin-potentiating factor (BPF) present in the venom of Botrops jararaca. Br J Pharmacol Chem-iother1965; 9: 2583–93.
10.
OndettiM.A., WilliamsN.J., SaboE.F., PluscecJ., CleaverE.R., KocyO.Angiotensin converting enzyme inhibitors from the venom of Botrops jararaca: isolation, elucidation of structure and synthesis. Biochemistry1971; 10: 4033–9.
11.
OndettiM.A., RubinB., CushmanD.W.Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science1977; 196: 441–4.
12.
IkemotoF., YamamotoK.Renin angiotensin system in the aqueous humor of rabbits, dogs and monkeys. Exp Eye Res1978; 27: 723–5.
VitaJ.B., AndersonJ.A., HulemC.D., LeopoldI.H.Angiotensin-converting enzyme activity in ocular fluids. Invest Ophthalmol Vis Sci1981; 20: 255–7.
15.
WeinrebR.N., DandmanR., RyderMl, FribergT.R.Angiotensin-converting enzyme activity in human aqueous humor. Arch Ophthalmol1985; 103: 34–6.
16.
SramekS.J., WallowI.H.L., DayR.P., EhrlichE.N.Ocular renin-angiotensin immunohistochemical evidence for the presence of prorenin in eye tissue. Invest Ophthalmol Vis Sci1988; 29: 1749–52.
KaufmanP.L., BaranyE.H.Adrenergic drug effects on aqueous outflow facility following muscle retrodisplace-ment in the cynomolgus monkey. Invest Ophthalmol Vis Sci1981; 20: 644–51.
19.
CostagliolaC., Di BenedettoR., De CaprioL.Angiotensin converting enzyme inhibitor (SQ 14225) oral administration and intraocular pressure in man. Proc X Intern Congr of Eye Res, Stresa (Italy), 20-25 Sept S 24, 76. 1992.
20.
BrogdenR.N., ToddP.A., SorkimE.M.Captopril. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs1988; 36: 540–600.
21.
KranezisT.A., MurphyM.B., WeberR.R., NelsonK.S., TripathiB.J., TripathiR.C.Effects of selective dopamine-1-receptor activation on intraocular pressure in man. Exp Eye Res1988; 47: 689–98.
22.
SossiN., AndersonD.R.Blockage of axonal transport in optic nerve induced by elevation of intraocular pressure. Arch Ophthalmol1982; 101: 94–8.
23.
ConstadW.H., FioreP., SamsonC., CinottiA.A.Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open angle glaucoma. Am J Ophthalmol1988; 105: 674–7.
24.
OparilS., SkidgelR.A.The renin-angiotensin system. N Engl J Med1974; 291: 389–93.
25.
RegoliD., BarabeJ.Pharmacology of bradykinin and related kinins. Pharmacol Reviews1980; 22: 1–45.
26.
ErdosE.G., SkidgelR.A.The angiotensin I converting enzyme. Lab Invest1987; 56: 345–8.
27.
CamrasC.B., BitoL.Z.Reduction of intaocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2alpha. Curr Eye Res1981; 1: 205–9.
28.
SternF.A., BitoL.Z.Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2alpha on cat and rhesus monkey eyes. Invest Ophthalmol Vis Sci1982; 22: 588–98.
29.
LeeP., PodosS.M., SeverinC.Effect of prostaglandin F2alpha on aqueous humor dynamics in rabbit, cat and monkey. Invest Ophthalmol Vis Sci1984; 25: 1087–93.
30.
LottiV.J., PawlowskiN.Prostaglandins mediate the hypotensive action of the angiotensin converting enzyme inhibitor MK 422 (enalaprilat) in African green monkeys. J Ocul Pharmacol1990; 8: 1–7.
31.
BaranyE.H., RohenJ.W.Localized contraction and relaxation within the ciliary muscle of the vervet monkey (cer-copithecus ethiops). In: RohenJ.W., ed. The structure of the eye: second symposium.Stuttgart: Schattauer-Verlag, 1965; 287–311.
32.
BillA.Effects of atropine and pilocarpine on aqueous humor dynamics in cynomolgus monkeys (macaca irus). Exp Eye Res1976; 6: 120–5.
33.
ZulaufM., FlammerJ.Der Einfluss von Enalapril auf der intraokularen Druk: Widerspruchliche Pilot studien?Klin Mbl Augenheilk1988; 192: 609–12.
34.
WatkinsR.W., BaumT., TedescoR.P., PulaK., BarnettA.Systemic effects resulting from topical ocular administration of SC 33861, a novel ACE inhibitor ocular hypotensive agent. J Ocul Pharmacol1988; 4: 93–100.
35.
VogtB.P., GodmanD.R.Effects of inhibition of angiotensin converting enzyme and carbonic anhydrase on fluid production by ciliary process, choroid plexus and pancreas. J Ocul Pharmacol1989; 5: 303–11.
36.
AbramsK.L., BrooksD.E., LarattaL.J., BranhillM.A., Frazi-erD.Angiotensin converting enzyme system in the normal canine eye: pharmacological and physiological aspects. J Ocul Pharmacol1991; 7: 41–51.
37.
Ai-SereitiM.R., TurnerP.Effect of captopril (an angiotensin converting enzyme inhibitor) on intraocular pressure in healthy human volunteers. J Ocul Pharmacol1989; 5: 1–5.
38.
SinghviS.M., McKinstryD.N., ShanJ.M., WillardD.A., Mig-dalofD.H.Effect of food on the bioavailability of captopril in healthy subjects. J Clin Pharmacol1982; 22: 135–40.
39.
IzumiJ., HondaM., HatnoM., KawaharaY.Influence of food on the clinical effect of angiotensin I converting enzyme inhibitors (SQ 14225). Tohoku J Exp Med1983; 139: 279–86.
